Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818919 | 0.93 | EGFR (0.62) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118521 | 0.85 | EGFR (0.57) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118509 | 0.85 | EGFR (0.63) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL13818914 | 0.84 | EGFR (0.67) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118507 | 0.84 | EGFR (0.75) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118523 | 0.78 | EGFR (0.65) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL13818831 | 0.77 | EGFR (0.62) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL642741 | 0.77 | EGFR (0.81) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118514 | 0.77 | EGFR (0.75) | EGFRHDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL10118517 | 0.76 | HDAC3 (0.76) | EGFRHDAC3HDAC1HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547781-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | EGFR 1/4885HDAC3 15/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.